Pfizer Claws Deeper Into The Obesity Space With $4.9 Billion Metsera Deal

Group 1: Acquisition Details - Pfizer is acquiring Metsera for $4.9 billion to strengthen its position in the obesity treatment market [1][3] - Metsera is a clinical-stage biotech company developing multiple weight-loss approaches, including a GLP-1-targeting drug and a monthly amylin-mimicking drug [2] Group 2: Market Impact - Following the acquisition announcement, Metsera's shares surged over 61% to $53.75, while Pfizer's stock rose 1.4% to $24.35 in premarket trading [3]